Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Financing Activities (2023 - 2025)

Immunome's Cash from Financing Activities history spans 3 years, with the latest figure at $432.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 2054.82% year-over-year to $432.8 million; the TTM value through Dec 2025 reached $640.4 million, up 166.23%, while the annual FY2025 figure was $640.4 million, 166.23% up from the prior year.
  • Cash from Financing Activities reached $432.8 million in Q4 2025 per IMNM's latest filing, up from $45.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $432.8 million in Q4 2025 to a low of -$55000.0 in Q2 2025.
  • Average Cash from Financing Activities over 3 years is $90.7 million, with a median of $45.4 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: soared 645326.47% in 2024, then tumbled 107.93% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $55.5 million in 2023, then plummeted by 63.81% to $20.1 million in 2024, then skyrocketed by 2054.82% to $432.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Cash from Financing Activities are $432.8 million (Q4 2025), $45.4 million (Q3 2025), and -$55000.0 (Q2 2025).